Prostate cancer (PCa) management has entered an era of unprecedented therapeutic and diagnostic capability, yet substantial gaps between evidence-based care and real-world practice persist across the disease continuum. These gaps—spanning diagnostic delays, undertreatment, suboptimal adherence, and inadequate longitudinal monitoring—translate directly into compromised patient outcomes, including accelerated disease progression, reduced survival, and diminished quality of life. This narrative synthesizes recent evidence to identify modifiable system- and patient-level barriers and proposes pragmatic strategies to close these gaps.
Diagnostic Delays: From Screening Through Definitive Diagnosis
Diagnostic delays in prostate cancer arise from fragmented screening protocols, prolonged referral pathways, and inequitable access to advanced imaging. A 2025 systematic review of 11 international clinical practice guidelines revealed that only 14% of cited studies explicitly examined optimal PSA retesting intervals; remarkably, 91% of guidelines recommended 2–4 year intervals based on evidence that did not support these recommendations9. This evidence-practice misalignment contributes to variable screening practices and delayed detection of high-risk disease in underserved populations.
The consequences of diagnostic delays manifest as stage migration toward more advanced disease at presentation. Analysis of the National Cancer Database (2004–2016) documented a proportional increase in high-risk prostate cancer diagnoses from 11.8% to 20.4% (P<0.001), suggesting either increased detection sensitivity or delays allowing progression to higher-grade disease before diagnosis1. Geographic and socioeconomic disparities compound these delays: patients residing >96 km from treatment centers had 2.53-fold higher odds of receiving prostatectomy rather than radiotherapy (95% CI: 2.40–2.67), suggesting access barriers influence not only timeliness but also appropriateness of treatment selection1.
Advanced imaging modalities offer potential solutions but remain underutilized. A large-scale multicenter validation study demonstrated that a multimodal machine learning model incorporating biparametric MRI radiomics reduced unnecessary biopsies by 22.7% compared to PI-RADS scoring alone, while maintaining superior diagnostic accuracy (AUC 0.91 vs 0.85, P<0.001)5. However, implementation barriers—including equipment costs, radiologist expertise requirements, and reimbursement structures—limit real-world adoption, particularly in rural and resource-limited settings.
PSMA-PET imaging exemplifies both the promise and challenge of precision diagnostics. Retrospective analysis of 568 patients post-radiotherapy showed that PSMA-PET performed before reaching Phoenix biochemical recurrence criteria (PSA rise ≥2.0 ng/mL) identified 76.6% with PSMA-avid lesions, with 75.9% eligible for local salvage therapy versus only 45.0% of those imaged after meeting Phoenix criteria (OR 3.84, P<0.001)8. Early detection translated to prolonged ADT-free survival and reduced progression to castration-resistant disease. Yet access remains limited by cost, availability, and lack of consensus on optimal timing thresholds313.
Undertreatment: Missed Opportunities for Intensification
Undertreatment in prostate cancer manifests in two critical domains: underuse of definitive local therapy in high-risk localized disease and insufficient treatment intensification in metastatic settings. The same National Cancer Database analysis revealing demographic disparities in treatment selection showed that Black men were 43% less likely than white men to undergo prostatectomy for high-risk disease (OR 0.57; 95% CI: 0.55–0.59; P<0.001), and men with government-based insurance had 36% lower odds of surgical management compared to privately insured patients (OR 0.64; 95% CI: 0.62–0.66; P<0.001)1. Treatment at academic facilities was strongly associated with prostatectomy (OR 2.57; 95% CI: 2.45–2.69), revealing institutional-level variation that cannot be explained by clinical factors alone.
In metastatic hormone-sensitive prostate cancer (mHSPC), the evidence for treatment intensification with androgen receptor pathway inhibitors (ARPIs) or docetaxel is robust, yet real-world implementation remains inconsistent. A 2024 multicenter retrospective study comparing abiraterone, enzalutamide, and apalutamide in 668 high-risk mHSPC patients found no significant differences in time to castration-resistant prostate cancer (CRPC), overall survival, or cancer-specific survival among the three agents10. However, the proliferation of treatment options has paradoxically increased clinical uncertainty about optimal sequencing and patient selection, potentially leading to both undertreatment (when clinicians defer intensification) and inappropriate treatment selection7.
For metastatic CRPC (mCRPC), a 2024 systematic review of 28 clinical trials identified that PARP inhibitor plus ARPI combinations improve radiographic progression-free survival particularly in BRCA1/2-altered patients, and that AKT inhibitor ipatasertib combined with abiraterone extends progression-free survival in patients with PTEN loss or PIK3CA/AKT1/PTEN alterations4. Yet biomarker-driven treatment selection remains underutilized, with many patients receiving sequential empiric therapies rather than molecularly guided intensification strategies1932.
The 2025–2026 updates to NCCN, AUA, and EAU guidelines emphasize treatment intensification but acknowledge ongoing challenges: shared decision-making must balance prior treatment exposures, biomarker profiles, disease extent, symptoms, and side effect risks—a complexity that requires multidisciplinary expertise often unavailable in community settings424445.
Treatment Adherence: The Hidden Barrier to Optimal Outcomes
Treatment adherence represents a critical yet frequently overlooked determinant of prostate cancer outcomes. Real-world US data demonstrate high medication possession ratios for oral ARPIs—mean MPR >90% for abiraterone and enzalutamide in multiple retrospective claims analyses46. However, more stringent proportion-of-days-covered (PDC) measures reveal lower adherence: only 60.8% of patients on oral relugolix (GnRH antagonist) achieved PDC ≥80% at 12 months compared to 46.3% on injectable GnRH agonists47.
More concerning, approximately 40% of mCRPC patients experience subtherapeutic abiraterone exposure (Cmin <8.4 ng/mL) at standard dosing21. Pharmacokinetic-guided interventions—primarily food intake modifications—successfully corrected exposure in 86% of cases, eliminating the survival disadvantage historically associated with low exposure. This finding underscores that treatment "adherence" encompasses not only pill-taking but also optimal medication administration practices.
The ARCHES trial secondary analysis demonstrated the clinical significance of achieving deep biochemical response: patients reaching undetectable PSA (<0.2 ng/mL) on enzalutamide experienced an 86% reduced risk of radiographic progression (HR 0.14; 95% CI: 0.09–0.23) and 76% reduced risk of death (HR 0.24; 95% CI: 0.17–0.34) compared to those with detectable PSA22. Similarly, in de novo mHSPC, patients achieving both ≥95% PSA decline and time-to-PSA-nadir ≥6 months showed superior progression-free survival (HR 0.56; 95% CI: 0.34–0.91) and overall survival (HR 0.50; 95% CI: 0.26–0.97)2.
Barriers to adherence are multifactorial. A comprehensive review identified financial toxicity as a primary driver: high out-of-pocket costs incentivize dose skipping or splitting, with Black and Hispanic Medicare beneficiaries reporting cost-related nonadherence rates of 35% and 37% respectively versus 27% for white patients48. Complex dosing schedules—particularly food-medication interactions—challenge sustained adherence, as does polypharmacy (80% of patients ≥65 years take ≥5 concurrent medications). Adverse events, drug-drug interactions, cognitive impairment, and lack of care partner support further erode adherence48.
Monitoring and Follow-up: Insufficient Surveillance Across the Continuum
Longitudinal monitoring gaps compromise early detection of progression and delay therapeutic adjustments. Active surveillance (AS) exemplifies this challenge: SEER-Medicare population-based data (2010–2015) revealed that only 81% of men on AS received PSA testing within 1–2 years, 33% underwent surveillance biopsy, and merely 10% received MRI scans50. Compliance worsened over time, with only 12.9% undergoing biopsy by year 3 and 5.9% by year 7. At 5-year follow-up, only 11.1% met comprehensive Sunnybrook/PRIAS protocol standards (≥14 PSAs and ≥2 biopsies), and just 5.0% fulfilled Johns Hopkins criteria (≥10 PSAs and ≥4 biopsies)49.
Socioeconomic and racial disparities profoundly impact monitoring quality. Black men on AS were 40% less likely to receive PSA testing (adjusted rate ratio 0.60; 95% CI: 0.53–0.69) and had 60% lower MRI utilization compared to non-Black men50. Men in the highest income quintile were 60% more likely to undergo MRI (ARR 1.60; 95% CI: 1.15–2.27) than those in the lowest quintile50.
Biomarker utilization for risk stratification remains limited. While restriction spectrum imaging (RSI)-MRI achieved the highest discriminatory power for predicting AS upgrading (AUC 0.84; 95% CI: 0.71–0.96)52, and polygenic risk scores demonstrated modest incremental value (23–27% increased hazard per SD increase)54, these tools have not been systematically integrated into AS protocols. Similarly, despite evidence that germline and somatic DNA repair gene testing identifies actionable alterations in approximately 25% of mCRPC patients55, clinical implementation in earlier disease stages remains nascent.
Post-treatment surveillance also suffers from protocol inconsistency. PSMA-PET imaging detects biochemical recurrence at remarkably low PSA values—25.2% positivity at PSA ≤0.2 ng/mL and 55.6% at PSA <0.01 ng/mL5657—yet current guidelines lack standardized recommendations for PSMA-PET timing and thresholds913. A 2023 international consensus statement identified development of dynamic, risk-adjusted surveillance approaches as the highest research priority, acknowledging substantial practice variation across settings53.
Care Coordination, Guideline Concordance, and Equity
Multidisciplinary team (MDT) engagement and guideline-concordant care significantly influence outcomes, yet access remains uneven. The 2024 US Prostate Cancer Conference developed 34 consensus recommendations through modified Delphi process specifically to address practical clinical questions where level 1 evidence is lacking19. The 2025–2026 EAU guidelines now explicitly recommend discussing all patients with hormone-sensitive metastatic disease in MDT settings and offering bone protective agents to men on long-term ADT plus ARPI4445. However, these recommendations presume infrastructure—specialized expertise, coordinated scheduling, advanced imaging access—differentially available across academic versus community centers and urban versus rural settings.
The 15-year ProtecT trial results, showing similar prostate cancer-specific mortality across active monitoring, prostatectomy, and radiotherapy (3.1%, 2.2%, and 2.9% respectively)35, underscore that treatment selection must be individualized and preference-sensitive. Yet achieving truly shared decision-making requires time, health literacy support, and cultural competence often lacking in overburdened systems.
Implications and Strategies for Practice Improvement
Closing these gaps requires coordinated action across multiple levels. Rapid diagnostic pathways integrating risk-stratified MRI protocols and PSMA-PET for appropriate indications can reduce time-to-treatment while minimizing overdiagnosis. Standardized AS protocols incorporating MRI surveillance and patient-reported outcomes, coupled with decision support tools embedded in electronic health records, can improve monitoring adherence. Financial navigation programs addressing out-of-pocket costs and medication access barriers are essential to reduce treatment disparities. Pharmacokinetic monitoring and administration counseling can optimize ARPI exposure. Expanding access to germline and somatic genomic testing enables biomarker-driven treatment intensification. Finally, regionalized MDT models leveraging telehealth can extend specialist expertise to underserved populations.
Current evidence indicates that diagnostic delays, undertreatment, suboptimal adherence, and deficiencies in longitudinal monitoring are not unavoidable features of prostate cancer care, but rather modifiable gaps in clinical practice for which evidence-based corrective strategies already exist. The systematic integration of these approaches into routine care may therefore represent an important next step in improving the quality and outcomes of prostate cancer management.